Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase

Prithviraj Bose, Haeseong Park, Jawad Al-Khafaji, Steven Grant

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Despite the remarkable success of imatinib against Bcr-Abl, development of secondary resistance, most often due to point mutations in the Bcr-Abl tyrosine kinase (TK) domain, is quite common. Of these, the T315I "gatekeeper" mutation is resistant to all currently registered Bcr-Abl TK inhibitors (TKIs) with the notable exception of ponatinib (Iclusig™), which was very recently approved by the United States Food and Drug Administration (FDA). Besides ponatinib, numerous strategies have been developed to circumvent this problem. These include the protein synthesis inhibitor omacetaxine (Synribo®), and "switch-control" inhibitors. Dual Bcr-Abl and aurora kinase inhibitors represent another promising strategy. Finally, several promising synergistic combinations, such as TKIs with histone deacetylase inhibitors (HDACIs), warrant attention.

Original languageEnglish
Pages (from-to)18-20
Number of pages3
JournalLeukemia Research Reports
Volume2
Issue number1
DOIs
StatePublished - Jun 4 2013
Externally publishedYes

Keywords

  • Bcr-Abl
  • Gatekeeper mutations
  • HDAC inhibitors
  • T315I
  • Tyrosine kinase inhibitors

Fingerprint Dive into the research topics of 'Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase'. Together they form a unique fingerprint.

  • Cite this